4.49
4.49 (0%)
As of Apr 17, 2025
Exagen Inc. [XGN]
Source:
Company Overview
Exagen Inc is a medical technology company primarily focused on the design, development and commercialization of a next-generation portfolio of innovative testing products under our AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
| Country | United States |
| Headquarters | vista, california |
| Phone Number | (760) 560-1501 |
| Industry | services |
| CEO | John Aballi |
| Website | www.exagen.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $55.6 |
| Operating Profit | $-13.6 |
| Net Income | $-15.1 |
| Net Cash | $-14.5 |
Profit Ratios
| Gross Margin | $33.1 |
| Operating Margin | -24.5 |
| Profit as % of Revenues | -219.1% |
| Profit as % of Assets | -29.7% |
| Profit as % of Stockholder Equity | -158.4% |
Management Effectiveness
| Return on Equity | -158.4% |
| Return on Assets | -33.8% |
| Turnover Ratio | 109.5% |
| EBITA | $-13.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $44.7 |
| Total Liabilities | $35.1 |
| Operating Cash Flow | $-13.3 |
| Investing Cash Flow | $-0.5 |
| Financing Cash Flow | $-0.7 |
